Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 16 of 34

Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b (1 of 2)

The likelihood of achieving an SVR was similar for dual therapy with ribavirin plus pegylated interferon alfa-2b and ribavirin plus pegylated interferon alfa-2a (although the likelihood appeared to be slightly lower for dual therapy with ribavirin + pegylated interferon alfa 2b). The strength of evidence for this finding was rated moderate. Seven trials conducted in patients with hepatitis C virus (HCV) genotype 1, 2, 3 or 4 infection found that dual therapy with standard doses of pegylated interferon alfa-2b plus ribavirin was associated with a lower likelihood of achieving a sustained virologic response (SVR) than pegylated interferon alfa-2a plus ribavirin (pooled relative risk, 0.87; 95-percent confidence interval [95% CI], 0.80 to 0.95), with an absolute difference in SVR rates of 8 percentage points (95% CI, 3 to 14). Absolute SVR rates were 38–62 percent for dual therapy with pegylated interferon alfa-2b versus 41–71 percent for dual therapy with pegylated interferon alfa-2a.